openPR Logo
Press release

Osteosarcoma Pipeline Insights Report 2025 by DelveInsight: Mapping Innovative R&D Strategies, Clinical Advancements, Pharma Leadership, and Future Growth Potential in the Therapeutics Market

09-20-2025 12:22 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Osteosarcoma Pipeline Insights Report 2025 by DelveInsight:

DelveInsight's "Osteosarcoma Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Othe steosarcoma pipeline landscape. It covers the Osteosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Osteosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Osteosarcoma Pipeline? Click here to explore the therapies and trials making headlines @ Osteosarcoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Osteosarcoma Pipeline Report

* On 16 September 2025, Merck Sharp & Dohme LLC announced a study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
* DelveInsight's Osteosarcoma Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Osteosarcoma treatment.
* The leading Osteosarcoma Companies such as Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
* Promising Osteosarcoma Therapies such as Ceralasertib, Avelumab, Vactosertib, ZN-c3, Gemcitabine, Lenvatinib, Ifosfamide, Etoposide and others.

Want to know which companies are leading innovation in Osteosarcoma? Dive into the full pipeline insights @ Osteosarcoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Osteosarcoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Osteosarcoma Pipeline Report also highlights the unmet needs with respect to the Osteosarcoma.

Osteosarcoma Overview

Osteosarcoma, also known as osteogenic sarcoma, is a rare type of bone cancer that originates in the bones, specifically affecting the long bones like those around the knee and shoulder. This cancer primarily develops in children and teenagers who are still growing. The exact cause of osteosarcoma is not fully understood, although in some instances, there is a familial predisposition with at least one gene associated with an increased risk. The hallmark symptom of osteosarcoma is pain, which can start intermittently but usually progresses to become constant.

Osteosarcoma Emerging Drugs Profile

* HS-20093: Hansoh BioMedical R&D Company

HS-20093 is a novel B7-H3-targeted antibody-drug conjugate that consists of a fully humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. This innovative drug is being developed for the treatment of lung cancer, sarcoma, head and neck cancers, and other solid tumors through multiple phase I and II clinical trials in China. The mechanism of action (MOA) of HS-20093 involves the specific targeting of B7-H3, a transmembrane receptor highly prevalent on malignant cells, with the monoclonal antibody component. This targeting allows for the delivery of the topoisomerase inhibitor payload directly to the cancer cells, where it can exert its cytotoxic effects, potentially leading to tumor cell death and inhibition of tumor growth. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Osteosarcoma.

* ZN c3: Zentalis Pharmaceuticals

ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma.

* NPX267: Nextpoint Therapeutics

NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors. By blocking the binding of KIR3DL3 on exhausted T and NK cells to HHLA2 expressed on tumor cells, NPX267 may be able to reactivate tumor antigen-primed immune cells in HHLA2-expressing solid tumors. Preventing KIR3DL3-mediated immune suppression may enhance anti-tumor immune responses for patients with HHLA2-positive cancers - a tumor antigen expressed independently of PD-L1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Osteosarcoma.

If you're tracking ongoing Osteosarcoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Osteosarcoma Treatment Drugs [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Osteosarcoma Companies

Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.

Osteosarcoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Osteosarcoma Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Osteosarcoma Pipeline Report covers it all - check it out now @ Osteosarcoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Osteosarcoma Pipeline Report

* Coverage- Global
* Osteosarcoma Companies- Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
* Osteosarcoma Therapies- Ceralasertib, Avelumab, Vactosertib, ZN-c3, Gemcitabine, Lenvatinib, Ifosfamide, Etoposide and others.
* Osteosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Osteosarcoma Treatment landscape in this detailed analysis @ Osteosarcoma Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Osteosarcoma: Overview
* Osteosarcoma Pipeline Therapeutics
* Osteosarcoma Therapeutic Assessment
* Osteosarcoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HS-20093: Hansoh BioMedical R&D Company
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* NPX267: Nextpoint Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Osteosarcoma Key Companies
* Osteosarcoma Key Products
* Osteosarcoma- Unmet Needs
* Osteosarcoma- Market Drivers and Barriers
* Osteosarcoma- Future Perspectives and Conclusion
* Osteosarcoma Analyst Views
* Osteosarcoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteosarcoma-pipeline-insights-report-2025-by-delveinsight-mapping-innovative-rd-strategies-clinical-advancements-pharma-leadership-and-future-growth-potential-in-the-therapeutics-market]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/osteosarcoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Osteosarcoma Pipeline Insights Report 2025 by DelveInsight: Mapping Innovative R&D Strategies, Clinical Advancements, Pharma Leadership, and Future Growth Potential in the Therapeutics Market here

News-ID: 4190578 • Views:

More Releases from ABNewswire

Hose Bros Inc Leads the Way in Professional Power Washing Across Millsboro, DE
Hose Bros Inc Leads the Way in Professional Power Washing Across Millsboro, DE
Clean and well-maintained exteriors are essential for preserving both the appearance and integrity of buildings. Dirt, mold, algae, and grime accumulate over time, impacting not only curb appeal but also structural safety. With these concerns in mind, power washing has become one of the most effective ways to restore surfaces and protect properties from damage. By applying controlled pressure and precision techniques, power washing removes stubborn stains, organic buildup, and
Florida Luxury Homes Launches Comprehensive Real-Time Platform Featuring Over 36,000 Premium Properties Across the Sunshine State
Florida Luxury Homes Launches Comprehensive Real-Time Platform Featuring Over 36 …
Revolutionary MLS-integrated platform delivers 15-minute listing updates, connecting discerning buyers with Florida's most prestigious coastal and inland estates FLORIDA - October 10, 2025 - Florida Luxury Homes (floridaluxuryhomes.net) announces the launch of its innovative real estate platform, offering unprecedented access to more than 36,000 curated high-end properties throughout Florida's most coveted markets. The platform establishes a new standard for luxury real estate search through advanced technology and expert curation. The comprehensive portal
Setting the Benchmark for Washington Roofing Services: READY ROOF Inc. Leads the Way
Setting the Benchmark for Washington Roofing Services: READY ROOF Inc. Leads the …
Homeowners and businesses in Washington, IL now have even more reasons to feel secure under their roofs. READY ROOF Inc., a trusted name in the roofing industry, is proud to announce the expansion of its professional roofing services in Washington IL, offering homeowners unmatched craftsmanship, durability, and reliability. With a commitment to customer satisfaction and a proven track record, the company is strengthening its presence as the go-to provider for
Navigating Military Divorce with Compassion and Expertise: Gordon Law, P.C. - Brooklyn Family and Divorce Lawyer Expands Dedicated Legal Services
Navigating Military Divorce with Compassion and Expertise: Gordon Law, P.C. - Br …
Military Divorce is unlike traditional divorce in many ways. Issues such as child custody during deployment, the division of military pensions, health care benefits, and residency requirements can add multiple layers of complexity. At Gordon Law, P.C. - Brooklyn Family and Divorce Lawyer, the firm's commitment is to help military families navigate these challenges with compassion, clarity, and unmatched legal expertise. Divorce can be an emotionally and legally complex process, but

All 5 Releases


More Releases for Osteosarcoma

Osteosarcoma Drug Market Hits New High | Major Giants AstraZeneca,Pfizer,Amgen,
HTF MI just released the Global Osteosarcoma Drug Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Major companies profiled in Osteosarcoma Drug Market are: Pfizer, Amgen, Bayer,
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuti …
The Osteosarcoma market growth is driven by factors like increase in the prevalence of Osteosarcoma, investments in research and development, entry of emerging therapies during the study period 2019-2032. The Osteosarcoma market report [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Osteosarcoma market size, share, Osteosarcoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Osteosarcoma market
Exploring the Osteosarcoma Drug Market: Trends, Opportunities, and Challenges
Osteosarcoma, a rare and aggressive bone cancer primarily affecting adolescents and young adults, has garnered significant attention in the pharmaceutical sector due to its complex treatment requirements and evolving drug landscape. This guest post delves into the osteosarcoma drug market, providing insights into its current state, opportunities, challenges, and future trends. Introduction Osteosarcoma is the most common primary malignant bone tumor, often occurring in the long bones of the arms and legs.
Osteosarcoma Market Size, Share, Trends & Forecast - 2034
Overview: According to the IMARC Group, the osteosarcoma market exhibited a market size of US$ 880.9 Million in the year 2023 and is projected at a CAGR of 4.68% during 2024-2034. This can be attributed to the growing use of combination therapy involving neoadjuvant chemotherapy and surgical resection, which improves treatment outcomes in patients and reduces the risk of cancer relapse. The osteosarcoma market report offers a comprehensive analysis of the market
Osteosarcoma Market Report 2023-2033 | Industry Size, Growth and Latest Insights
Market Overview: The osteosarcoma market is expected to exhibit a CAGR of 4.87% during 2023-2033. The report offers a comprehensive analysis of the osteosarcoma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally,
Pediatric Osteosarcoma Therapeutics Market Insights, Forecast to 2031
The report extensively examines the global Pediatric Osteosarcoma Therapeutics market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Pediatric Osteosarcoma Therapeutics. For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global